Risk factors
Palvella Therapeutics (PVLA) risk factors
Item 1A of every Palvella Therapeutics, Inc. 10-K on file, and what changed from one year to the next.
- FY2025 10-K risk factors
83 risks, 82 new, 95 dropped, 1 reworded since the prior year. Palvella Therapeutics faces significant financial risks advancing QTORIN rapamycin for rare skin diseases through clinical trials without approved commercial products.
Filed Mar 31, 2026 - FY2024 10-K risk factors
96 risks. Palvella is an early-stage biopharmaceutical company with zero product revenue and substantial historical operating losses.
Filed Mar 31, 2025